Showing results (41-50 of 85) with videos related to
Sort By:
Pageof 9
Frontiers in Oncology|January 31, 2020
High-Dose Ipilimumab and High-Dose Interleukin-2 for Patients With Advanced MelanomaAnn W Silk, Howard L Kaufman, Brendan Curti, et al.Pigment Cell & Melanoma Research|February 18, 2018
A phase II trial of riluzole, an antagonist of metabotropic glutamate receptor 1 (GRM1) signaling, in patients with advanced melanomaJanice M Mehnert, Ann W Silk, J H Lee, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2014
Phase I dose-escalation study of onartuzumab as a single agent and in combination with bevacizumab in patients with advanced solid malignanciesRavi Salgia, Premal Patel, John Bothos, et al.Molecular Cancer Therapeutics|June 18, 2011
Rationally designed treatment for solid tumors with MAPK pathway activation: a phase I study of paclitaxel and bortezomib using an adaptive dose-finding approachJanice M Mehnert, Antoinette R Tan, Rebecca Moss, et al.Journal for Immunotherapy of Cancer|May 4, 2023
Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trialJason A Chesney, Igor Puzanov, Frances A Collichio, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 11, 2017
Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 StudyPatrick A Ott, Yung-Jue Bang, Dominique Berton-Rigaud, et al.BMC Cancer|March 6, 2019
Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancerJanice M Mehnert, Andrea Varga, Marcia S Brose, et al.JNCI Cancer Spectrum|December 16, 2022
Expanding access to early phase trials: the CATCH-UP.2020 experienceJoaquina C Baranda, Francisco J Diaz, Larry Rubinstein, et al.Cancer Chemotherapy and Pharmacology|August 30, 2019
A phase I trial of MK-2206 and hydroxychloroquine in patients with advanced solid tumorsJanice M Mehnert, Amanda D Kaveney, Jyoti Malhotra, et al.Journal of Translational Medicine|May 10, 2022
The "Great Debate" at Melanoma Bridge 2021, December 2nd-4th, 2021Paolo A Ascierto, Allison Betof Warner, Christian Blank, et al.Pageof 9